Evidence map›Paper›PMID 27350283›Full record

ArticleCancer medicine2016

Novel role of ASC as a regulator of metastatic phenotype.

Nagisa Okada, Chifumi Fujii, Tomio Matsumura, Masato Kitazawa, Ryuhei Okuyama, Shun'ichiro Taniguchi, Shigeaki Hida

Abstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Dual Role of Inflammasome Adaptor ASC in Cancer.Frontiers in cell and developmental biology · 2020
    Review
  4. Review
  5. Article
  6. Inflammasomes in Inflammation-Induced Cancer.Frontiers in immunology · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nagisa OkadaDepartment of Molecular Oncology, Institute of Pathogenesis and Disease Prevention, Graduate School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Chifumi FujiiDepartment of Molecular Oncology, Institute of Pathogenesis and Disease Prevention, Graduate School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan. chifumif@shinshu-u.ac.jp.
Tomio MatsumuraDepartment of Molecular Oncology, Institute of Pathogenesis and Disease Prevention, Graduate School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Masato KitazawaDepartment of Molecular Oncology, Institute of Pathogenesis and Disease Prevention, Graduate School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Ryuhei OkuyamaDepartment of Dermatology, School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Shun'ichiro TaniguchiDepartment of Molecular Oncology, Institute of Pathogenesis and Disease Prevention, Graduate School of Medicine, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Shigeaki HidaDepartment of Molecular and Cellular Health Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disorders of cytoskeletal remodeling and signal transduction are frequently involved in cancer progression. In particular, apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) has been reported a proapoptotic molecule that is epigenetically silenced in several human cancers. ASC is a well-characterized adaptor protein involved in the formation of multiprotein oligomers, called inflammasomes, and plays a crucial role in the activation and secretion of interleukin-1β and interleukin-18 in innate immune cells. However, the function of ASC in the regulation of tumor progression remains elusive. The present investigation examined the involvement of ASC in cancer progression and the acquisition of metastatic ability. To determine the effect of ASC depletion in in vitro and in vivo model systems, ASC was stably knocked down in B16 murine melanoma cell lines using retroviral transduction of shRNA. ASC suppression increased the motility of B16BL6 cells in scratch assays and augmented invasiveness as assessed by a Matrigel-coated transwell system. Invadopodia formation and Src phosphorylation level were markedly enhanced in ASC-knockdown cells as well. Since caspase-8 has been reported to enhance cellular migration by Tyr380 phosphorylation via Src, we examined Tyr380 phosphorylation of caspase-8 in ASC-knockdown cells and found it to be elevated in ASC-knockdown cells but attenuated by z-VAD-fmk or z-IETD-fmk. Moreover, ASC ablation increased pulmonary metastasis in mice after intravenous injection of B16BL6 cells. Our cumulative findings indicate that ASC suppresses cancer metastasis and progression via the modulation of cytoskeletal remodeling and the Src-caspase-8 signaling pathway.

Indexed as

Gene Expression Regulation, NeoplasticPhenotypeSignal TransductionAnimalsCARD Signaling Adaptor ProteinsCaspase 8Cell MovementCell ProliferationDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesFemaleGene Knockdown TechniquesGene SilencingLung NeoplasmsMelanoma, ExperimentalMiceCARD Signaling Adaptor ProteinsCaspase 8Extracellular Signal-Regulated MAP KinasesPycard protein, mousesrc-Family KinasesASCinvadopodiametastasismotilitySrc signaling pathway

Identifiers

PMID27350283
PMCPMC5055161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.